Get our introductory offer at only
*$0.99/month for first 3 months
$29.90/month for the next 9 months
ELI Lilly staked its claim for a slice of sales in a new class of breast cancer drugs on Sunday as clinical data showed adding its medicine abemaciclib to standard therapy reduced the risk of disease progression by 46 per cent.
Experts at the European Society for Medical